PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumorsMónica Tang, Michael Friedländer, Alison Davis et al.|Gynecologic Oncology|2019Cited by 88
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitroPhilip O'Brien, R. L. Sutherland, Michael J. Davies et al.|British Journal of Cancer|2008Cited by 69
MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcomeJennifer A. Byrne, Philippa M. O’Brien, Sanaz Maleki et al.|BMC Cancer|2010Cited by 64
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progressionPeey‐Sei Kok, Rachel O’Connell, Peter Grant et al.|Journal of Gynecologic Oncology|2019Cited by 26
Paragon (ANZGOG-0903)Anthony Bonaventura, Michael Friedländer, Rachel O’Connell et al.|International Journal of Gynecological Cancer|2017Cited by 22